"Metered Dose Inhalers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A small aerosol canister used to release a calibrated amount of medication for inhalation.
| Descriptor ID |
D036501
|
| MeSH Number(s) |
E07.605.750
|
| Concept/Terms |
Metered Dose Inhalers- Metered Dose Inhalers
- Inhaler, Metered Dose
- Metered Dose Inhaler
- MDI (Inhalers)
- Inhalers, Metered Dose
|
Below are MeSH descriptors whose meaning is more general than "Metered Dose Inhalers".
Below are MeSH descriptors whose meaning is more specific than "Metered Dose Inhalers".
This graph shows the total number of publications written about "Metered Dose Inhalers" by people in this website by year, and whether "Metered Dose Inhalers" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 4 | 0 | 4 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Metered Dose Inhalers" by people in Profiles.
-
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. Respir Med. 2022 06; 197:106857.
-
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS. Int J Chron Obstruct Pulmon Dis. 2021; 16:179-189.
-
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial. Ther Adv Respir Dis. 2021 Jan-Dec; 15:17534666211034329.
-
Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax. 2020 09; 75(9):735-743.
-
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. Respir Res. 2020 May 25; 21(1):128.
-
Pathways for Improving Inpatient Pediatric Asthma Care (PIPA): A Multicenter, National Study. Pediatrics. 2020 06; 145(6).
-
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. Int J Chron Obstruct Pulmon Dis. 2020; 15:99-106.
-
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6??g and 160/18/9.6??g using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respir Med. 2019 Oct - Nov; 158:59-66.
-
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018 10; 6(10):747-758.
-
Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD. Chest. 2017 12; 152(6):1169-1178.